PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
24955765-9	2014	Finally, uPAR PET imaging using (64)Cu-DOTA-AE105 detected all small, disseminated metastatic foci when compared with bioluminescence imaging in a cohort of animals during the treatment study.	1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid	36-43	plasminogen activator, urokinase receptor	Homo sapiens	9-13	
22739362-10	2012	RESULTS: uPAR-positive HT-29 xenograft was clearly visualized by PET/CT imaging using (64)Cu-DOTA-AE105.	1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid	90-97	plasminogen activator, urokinase receptor	Homo sapiens	9-13	
23166959-0	2004	(177)Lu-Labeled DOTA-conjugated AE105 peptide (Asp-Cha-Phe-(d)Ser-(d)Arg-Tyr-Leu-Trp-Ser-CONH2) The urokinase type plasminogen activator (uPA) receptor (uPAR) is implicated in bacterial infections, hemoglobinuria (the paroxysmal nocturnal type), and cancers such as those of the colon-rectum, stomach, and the mammary glands (1).	1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid	16-20	plasminogen activator, urokinase receptor	Homo sapiens	100-151	
23166959-0	2004	(177)Lu-Labeled DOTA-conjugated AE105 peptide (Asp-Cha-Phe-(d)Ser-(d)Arg-Tyr-Leu-Trp-Ser-CONH2) The urokinase type plasminogen activator (uPA) receptor (uPAR) is implicated in bacterial infections, hemoglobinuria (the paroxysmal nocturnal type), and cancers such as those of the colon-rectum, stomach, and the mammary glands (1).	1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid	16-20	plasminogen activator, urokinase receptor	Homo sapiens	153-157	
22213823-3	2012	METHODS: To accomplish our objective, a linear, high-affinity uPAR peptide antagonist, AE105, was conjugated with DOTA and labeled with (64)Cu ((64)Cu-DOTA-AE105).	1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid	114-118	plasminogen activator, urokinase receptor	Homo sapiens	62-66	
22213823-3	2012	METHODS: To accomplish our objective, a linear, high-affinity uPAR peptide antagonist, AE105, was conjugated with DOTA and labeled with (64)Cu ((64)Cu-DOTA-AE105).	1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid	148-155	plasminogen activator, urokinase receptor	Homo sapiens	62-66	
22213823-10	2012	CONCLUSION: Our results clearly demonstrate that the peptide-based PET tracer (64)Cu-DOTA-AE105 enables the noninvasive quantification of uPAR expression in tumors in vivo, thus emphasizing its potential use in a clinical setting to detect invasive cancer foci and for individualized cancer therapy.	1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid	85-89	plasminogen activator, urokinase receptor	Homo sapiens	138-142	
18676745-5	2008	A linear, high-affinity uPAR-binding peptide antagonist AE105 was conjugated with 1,4,7,10-tetraazadodecane-N,N",N"",N"""-tetraacetic acid (DOTA) and labeled with (64)Cu for microPET imaging of mice bearing U87MG human glioblastoma (uPAR positive) and MDA-MB-435 human breast cancer (uPAR negative).	1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid	140-144	plasminogen activator, urokinase receptor	Homo sapiens	24-28	
18676745-5	2008	A linear, high-affinity uPAR-binding peptide antagonist AE105 was conjugated with 1,4,7,10-tetraazadodecane-N,N",N"",N"""-tetraacetic acid (DOTA) and labeled with (64)Cu for microPET imaging of mice bearing U87MG human glioblastoma (uPAR positive) and MDA-MB-435 human breast cancer (uPAR negative).	1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid	140-144	plasminogen activator, urokinase receptor	Homo sapiens	233-237	
18676745-5	2008	A linear, high-affinity uPAR-binding peptide antagonist AE105 was conjugated with 1,4,7,10-tetraazadodecane-N,N",N"",N"""-tetraacetic acid (DOTA) and labeled with (64)Cu for microPET imaging of mice bearing U87MG human glioblastoma (uPAR positive) and MDA-MB-435 human breast cancer (uPAR negative).	1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid	140-144	plasminogen activator, urokinase receptor	Homo sapiens	233-237	
18676745-6	2008	RESULTS: Surface plasmon resonance measurements show that AE105 with DOTA conjugated at the alpha-amino group (DOTA-AE105) has high affinity toward uPAR.	1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid	69-73	plasminogen activator, urokinase receptor	Homo sapiens	148-152	
18676745-7	2008	microPET imaging reveals a rapid and high accumulation of (64)Cu-DOTA-AE105 in uPAR-positive U87MG tumors (10.8 +/- 1.5%ID/g at 4.5 hours, n = 3) but not in uPAR-negative MDA-MB-435 tumors (1.2 +/- 0.6%ID/g at 4.5 hours, n = 3).	1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid	62-69	plasminogen activator, urokinase receptor	Homo sapiens	79-83	
35396143-9	2022	CONCLUSIONS: uPAR is abundantly expressed by MPS cells in atherosclerotic plaques and can be visualized by the novel PET tracer (64Cu)Cu-DOTA-AE105 that may non-invasively detect extracellular matrix remodeling during atherogenesis.	1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid	134-141	plasminogen activator, urokinase receptor	Homo sapiens	13-17